Glycyx is at the forefront of cancer treatment by addressing the overlooked issue of opioids reducing immunotherapy effectiveness. As a biotech firm entering Phase 2, we are pioneering a novel therapy to ensure pain management doesn't compromise anti-PD1/PD-L1 treatments. Our goal: to greatly enhance survival and quality of life for cancer patients globally.
The integration of opioids into cancer care, vital for managing the severe pain experienced by patients, inadvertently presents a significant challenge in oncological treatment effectiveness. Recent scientific insights reveal that opioids, beyond their analgesic properties, undermine the efficacy of immune checkpoint inhibitors (ICIs) — a cornerstone in modern cancer therapy known for their potential to significantly improve survival in various solid tumors. This interaction leads to what is identified as Opioid-Induced Immunotherapy Failure (OIIF), a condition where the immunosuppressive and pro-angiogenic effects of opioids diminish the body's immune response to cancer cells, thereby compromising the effectiveness of ICIs.
Glycyx proposes a groundbreaking solution to this critical challenge with the development of a small molecule peripherally restricted opioid antagonist designed to counteract the negative effects of opioids on immune checkpoint inhibitor therapies without compromising pain relief. This novel drug, intended as a combination therapy with ICIs, axelopran will:
• Reverse Opioid-Induced Immunosuppression
• Enable Re-challenge in Treatment-Resistant Cancers
• Robust Safety Credentials Established in Earlier Studies
• Demonstrated Efficacy in Preclinical Studies
• Phase 2 Ready, CMC Complete, Clinical Supply Built through Phase 3
Company Details
- Employees
- 3
- Founded
- -
- Address
- 5654 Geary Blvd,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.glycyx.com/
- Keywords
- Oncology, Acute Care, Therapeutics, Immuno-oncology, Ophthalmology, Pharmaceutical, Checkpoint Inhibitors, Head and Neck Cancer, Non-Small Cell Lung Cancer, Phase 2, Hepatocellular Cancer.
- HQ
- San Francisco, California
Glycyx Questions
Glycyx's website is http://www.glycyx.com/
Glycyx's LinkedIn profile is https://www.linkedin.com/company/glycyx
Glycyx has
3 employees.
View email and phone details for 3
employees at Glycyx.
Glycyx's industry is
Pharmaceutical Manufacturing
Glycyx's top competitors are
Secarna Pharmaceuticals,
Egaceutical Corporation,
Uplifted Yoga, Llc,
Sound Healing Project,
Sidewinder Therapeutics, Inc,
Denovo Biopharma,
Iolyx Therapeutics,
Purelight Power,
Eido Bio,
Genvivo, Inc..
Glycyx's categories are Pharmaceutical Manufacturing
Glycyx's founding year is 2020
